Stocks Health care IMMX
NASDAQ · Health careImmix Biopharma, Inc. (IMMX)
It posted a net loss of $39.9M. In fiscal 2025 capital spending exceeded operating cash flow by $24.7M. At June 30, 2026 it held $225.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Immix Biopharma, Inc.
- Net worth
- Immix Biopharma, Inc. has a market value (market cap) of $613.1M at the latest share price, and shareholders' equity of $228.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $23.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Immix Biopharma, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Immix Biopharma, Inc. does
Immix Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMMX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$29.4M | -$0.89 | -$24.7M |
| 2024 | n/a | -$21.6M | -$0.76 | -$15.8M |
| 2023 | n/a | -$15.4M | -$0.89 | -$11.4M |
| 2022 | n/a | -$8.2M | -$0.59 | n/a |
| 2021 | n/a | -$24.4M | -$6.64 | -$1.6M |
| 2021 | n/a | -$1.1M | -$0.34 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Immix Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- September 30, 2026Other event 8-K
- September 29, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- July 20, 2026Other event 8-K
- June 5, 2026Passive stake changed SCHEDULE 13G/A
- May 29, 2026
- May 21, 2026Other event 8-K
Insider trades
What the people running Immix Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | Hsu JasonDirector | Received as pay | 6,250 | - |
| May 22, 2026 | Buchan JaneDirector | Received as pay | 6,250 | - |
| May 22, 2026 | Chudnovsky YekaterinaDirector | Received as pay | 6,250 | - |
| May 22, 2026 | Chang Nancy TDirector | Received as pay | 6,250 | - |
| May 22, 2026 | Marquet MagdaDirector | Received as pay | 6,250 | - |
| May 22, 2026 | Adams Helen C.Director | Received as pay | 6,250 | - |
| May 22, 2026 | Ng CareyDirector | Received as pay | 6,250 | - |
| December 10, 2025 | Morris Gabriel SCFO, Director | Bought | 770 | $5.1K |
Who owns IMMX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| JANUS HENDERSON GROUP Ltd.13G, passive | 14% | August 13, 2026 |
| Saturn V Capital Management LP13G, passive with 1 related filers | 6.97% | February 17, 2026 |
| Eventide Asset Management, LLC13G, passive with 2 related filers | 5.6% | August 14, 2026 |
| BlackRock, Inc.13G, passive | 5.5% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 109 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 9,783,192 | new |
| Saturn V Capital Management LP | 4,658,429 | +964,844 |
| Eventide Asset Management, LLC | 3,891,019 | +1,342,000 |
| State Street Corp | 2,996,935 | +2,805,025 |
| BlackRock, Inc. | 2,989,972 | +2,521,595 |
| Deep Track Capital, LP | 2,775,000 | new |
| Vanguard Capital Management LLC | 2,507,122 | +719,128 |
| Opaleye Management Inc. | 2,345,000 | new |
| Millennium Management LLC | 2,066,426 | +316,226 |
| UBS Group AG | 1,941,817 | +1,864,985 |
| Marshall Wace, Llp | 1,794,908 | +153,356 |
| Wellington Management Group Llp | 1,473,409 | new |
| Great Point Partners LLC | 1,277,642 | +927,642 |
| Geode Capital Management, LLC | 1,201,097 | +737,713 |
| Velan Capital Investment Management LP | 1,085,000 | +345,000 |
| Bleichroeder LP | 1,000,000 | 0 |
| Logos Global Management LP | 1,000,000 | -225,000 |
| Franklin Resources Inc | 969,120 | +54 |
| Burkehill Global Management, LP | 544,118 | +250,000 |
| Ameriprise Financial Inc | 518,881 | new |
Insiders
9 insiders reported holding 3,481,947 shares in total, about $29.8M at the last price.
| Holder | Shares |
|---|---|
| Rachman Ilya MCEO and Chairman, Director | 1,141,683 |
| Hsu JasonDirector | 899,250 |
| Morris Gabriel SCFO, Director | 718,273426,844 held indirectly |
| Chang Nancy TDirector | 428,190 |
| Adams Helen C.Director | 181,004 |
| Marquet MagdaDirector | 52,342 |
| Buchan JaneDirector | 28,705 |
| Ng CareyDirector | 26,250 |
| Chudnovsky YekaterinaDirector | 6,250 |
Questions about IMMX
What does Immix Biopharma, Inc. do?
Immix Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as IMMX. Its shares trade on NASDAQ under the ticker IMMX.
What is Immix Biopharma, Inc.'s net worth?
Immix Biopharma, Inc. has a market value (market cap) of $613.1M at the latest share price, and shareholders' equity of $228.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Immix Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $39.9M.
When did Immix Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 27, 2026.
When is Immix Biopharma, Inc.'s next earnings report?
Immix Biopharma, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare IMMX with
Follow IMMX
Get an email when Immix Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Immix Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.